All In MedTech

Device Trial Radar · NCT03437967

Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning

Last checked: Nov 19, 2026Latest source record: Aug 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

12

Actual

Start

Aug 1, 2018

Primary completion

Jun 1, 2019

Study completion Jun 1, 2019

Sponsor

Lead sponsor
LiteCure LLCNot on our public-company list
Sponsor type
Industry
First posted
Feb 19, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will examine the effect of LASER photobiomodulation therapy on pain and opioid pain medication weaning on patients who are undergoing opioid pain medication weaning.

Conditions

  • Chronic Pain

Interventions

  • LightForce EXPiDevice

    LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compliance with Medical Opioid Use Reduction ProtocolTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sharp Alison DeRose Rehabilitation Center

    San Diego, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.